Drug interactions of medications commonly used in diabetes

Diabetes Spectrum

Volumn 19, Issue 4, 2006, Pages 202-211

  Triplitt, Curtis ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTACID AGENT; ANTIFUNGAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CISAPRIDE; CLARITHROMYCIN; DELAVIRDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; FERROUS SULFATE; FLUOXETINE; FLUVOXAMINE; GEMFIBROZIL; GLIPIZIDE; IRBESARTAN; LEVOTHYROXINE; LOSARTAN; PYRROLE DERIVATIVE; QUINIDINE; REPAGLINIDE; SULFONYLUREA; TERFENADINE; UNINDEXED DRUG; VERAPAMIL; ZAFIRLUKAST;

ALZHEIMER DISEASE; BIOAVAILABILITY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG COST; DRUG METABOLISM; DRUG POTENTIATION; DYSLIPIDEMIA; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL REFLUX; HEALTH CARE COST; HEALTH EDUCATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MORBIDITY; MORTALITY; MYASTHENIA GRAVIS; MYOPATHY; PERIPHERAL NEUROPATHY; QT PROLONGATION; REVIEW; STOMACH PARESIS; TORSADE DES POINTES;

EID: 33845367689     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.19.4.202     Document Type: Review

References (54)

1. American Society of Health-System Pharmacists: ASHP national concerns research report [article online]. Available from http://www.ashp.org/pr/survey. cfm
2. Zhou S, Chan SU, Goh BC, Eli C, Wei D, Min H, McLeod HL: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304, 2005
3. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW: Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 14:755-767, 2005
4. Malone DC, Hutchins DS, Haupert H, Hansten P, Duncan B, Van Bergen RC, Solomon SL, Lipton RB: Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 62:1983-1991, 2005
5. Hu Z, Yang X, Ho PCL, Chan SY Chan, Hen PWS, Chan E, Wei D, Koh HL, Zhow S: Herb-drug interactions: a literature review. Drugs 65:1239-1282, 2005
6. Sorenson JM: Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 8:293-308, 2002
7. Lexi-comp's Clinical Reference Library Online: Lexi-interact [article online]. Available from http://online.lexi.com/crlsql/servlet/crlonline
8. Rowland M, Tozer T: Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Baltimore, Md., Williams & Wilkins, 1995
9. Wahlin-Boll K, Melander A, Sartor G, Schersten B: Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy controls. Eur J Clin Pharmacol 18:279-283, 1980
10. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA: Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 17:1460-1464, 1994
11. Campbell NRC, Hasinoff BB, Stalts H, Rao B, Wong NCW: Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 117:1010-1013, 1992
12. Benet L, Hoener B: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121, 2002
13. Sikka R, Magauran B, Ulrich A, Shannon M: Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 12:1227-1235, 2005
14. Estabrook RW: The remarkable P450s: a historical overview of these versatile hemeprotein catalysts. FASEB J 10:202-204, 1996
15. Guengerich FP, Hosea NA, Parikh A, Bell-Parikh LC, Johnson WW, Gillam EMJ, Shimada T: Twenty years of biochemistry of human P450s: purification, expression, mechanism and relevance to drugs. Drug Metab Dispos 26:1175-1178, 1998
16. Hasler JA, Estabrook R, Murray M, Pikuleva I, Waterman M, Capdevila J, Holla V, Helvig C, Falck JR, Farrell G, Kaminsky LS, Spivack SD, Boitier E, Beaune P: Human cytochromes P450. Mol Aspects Med 20:1-137, 1999
17. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F: Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551, 1987
18. Bristol Myers Squibb: Glucophage (metformin HCl): prescribing information [article online]. Available from http://www.glucophage.com
19. Groop L, Eriksson CJ, Huupponen R, Ylikahri R, Pelkonen R: Roles of chlorpropamide, alcohol and acetaldehyde in determining the chlorpropamide- alcohol flush. Diabetologia 26:34-38, 1984
20. White JR, Campbell RK: Dangerous and common drug interaction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 29:789-802, 2000
21. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347-351, 2003
22. Novo Nordisk: Prandin (repaglinide): prescribing information [article online]. Available from http://www.prandin.com
23. Hatorp V, Hansen KT, Thomsen MS: Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 43:649-660, 2003
24. Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V: Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 23:1227-1231, 2000
25. Gilligan MA: Metformin and vitamin B12 deficiency. Arch Int Med 162:484-485, 2002
26. Kimura N, Okuda M, Inui K: Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 22:255-259, 2005
27. Dawson D, Conlon C: Case study: metformin-associated lactic acidosis: Could orlistat be relevant? Diabetes Care 26:2471-2472, 2003
28. Triplitt C, Reasner C, Isley W: Diabetes mellitus. In Pharmacotherapy: A Pathophysiologic Approach. 6th ed. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. New York, McGraw-Hill. p. 1333-1367
29. Baldwin SJ, Clark SE, Chenery RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 55:53-56, 1999
30. Niemi M, Backman JT, Neuvonen PJ: Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 76:239-249, 2004
31. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 77:404-414, 2005
32. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M: Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 89:1140-1145, 2004
33. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Diabetes Care 27:256-263, 2004
34. Lebovitz HE, Kreider M, Freed MI: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815-821, 2002
35. Isley WL: Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2:581-586, 2003
36. Takeda Pharmaceuticals and Eli Lilly: Actos (pioglitazone): prescribing information [article online]. Available from http://www.actos.com
37. GlaxoSmithKline: Avandia (rosiglitazone): prescribing information [article online]. Available from http://www.avandia.com
38. Ben-Ami H, Krivoy N, Nagachandran P, Roguin A, Edoute Y: An interaction between digoxin and acarbose. Diabetes Care 2:860-861, 1999
39. Morreale AP, Janetzky K: Probable interaction of warfarin and acarbose. Am J Health Syst Pharm 54:1551-1552, 1997
40. Unger T, Kaschina E: Drug interactions with angiotensin-receptor blockers: comparison with other antihypertensives. Drug Saf 26:707-720, 2003
41. Teo KK, Usuf S, Pfeffer M, Kober L, Hall A, Pogue J, Latini R, Collins R: Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence of absence of aspirin: a systematic review. Lancet 360:1037-1043, 2002
42. Fuhr U, Muller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, Staib HA: Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 58:45-53, 2002
43. Ho PC, Ghose K, Saville D, Wanwimolruk S: Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol 56:693-698, 2000
44. Christensen H, Asberg A, Holmboe AB, Berg KJ: Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol 58:515-520, 2002
45. Nakamura K, Ariyoshi N, Iwatsubo T, Fukunaga Y, Higuchi S, Itoh K, Shimada N, Nagashima K, Yokoi T, Yamamoto K, Horiuchi R, Kamataki T: Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull 28:882-885, 2005
46. Kaplan NM: Kaplan's Clinical Hypertension. 8th ed. Baltimore, Md., Williams & Wilkins, 2002
47. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A: Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197, 2006
48. Shitara Y, Hirano M, Sato H, Sugiyama Y: Gemfibrozil and its glucoronide inhibit the organic anion transporting polypeptide 2-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysys of the mechanism of the clinically relelvant drug-drug interact between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236, 2004
49. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB: Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467-494, 2005
50. FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861, 2005
51. Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109:III50-III57, 2004
52. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 289:1681-1690, 2003
53. Lexi-comp's Clinical Reference Library Online: Lexi-drugs [article online]. [Accessed 17 February 2005] Available at: http://online.lexi.com/ crlsql/servlet/crlonline
54. Merck: Zocor (simvastatin): prescribing information [article online]. Available from http://www.zocor.com